

May 5, 2017

The logo features the word "DCAT" in blue, "TOP" in orange with an upward-pointing arrow, and "Industry NEWS" in blue.

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

More successful NDA approvals
than any other. Delivered.

The Patheon logo is set against a background of blue and green bubbles. The tagline "A HEALTHIER WORLD. DELIVERED." is positioned below the company name.

1. [Allergan Completes \\$2.4-Billion Zeltiq Buy](#)

Allergan has completed a previously announced \$2.4-billion acquisition of Zeltiq Aesthetics, a medical technology company with a proprietary controlled-cooling body sculpting technology, which boosts Allergan's medical aesthetics portfolio. [Read More](#)

2. [AstraZeneca Partners for Respiratory Disease in \\$2-Billion+ Deal](#)

AstraZeneca has partnered with Pieris Pharmaceuticals to develop inhaled drugs for respiratory diseases in a deal worth up to more than \$2 billion. Pieris has proprietary technology for engineering proteins that can mimic antibodies. [Read More](#)

3. [Otsuka, Akebia Expand Anemia Collaboration in \\$865-Million Deal](#)

Otsuka Pharmaceutical has expanded a previous collaboration with Akebia Therapeutics for vadadustat, an anemia drug, by entering into a new collaboration and license agreement for Europe, China, and other territories in a transaction worth approximately \$865 million. [Read More](#)

4. [GSK in \\$139-Million Manufacturing Expansion](#)

GlaxoSmithKline (GSK) is investing \$139 million in its biopharmaceutical manufacturing site in Rockville, Maryland, which it gained with its \$3.6-billion acquisition of Human Genome Sciences (HGS) in 2012. The investment will expand bulk drug substance capacity for a lupus drug co-developed between GSK and HGS. [Read More](#)

5. [Daiichi Sankyo Expands ADC Manufacturing](#)

Daiichi Sankyo is making an initial Japanese yen 15 billion (\$135 million) investment into three of its manufacturing plants in Japan to expand manufacturing capabilities for its antibody drug conjugate (ADC) pipeline. [Read More](#)

6. [Shire Partners for Eye Disease Drug in \\$535-Million Deal](#)

Shire has partnered with Parion Sciences, a biopharmaceutical company, by which Shire gains exclusive worldwide rights to develop and commercialize an investigational drug for treating dry-eye disease in a deal worth up to \$535 million. [Read More](#)

7. [Julphar Gulf Pharmaceutical Opens Solid/Liquid Dosage Mfg Plant](#)

Julphar Gulf Pharmaceutical Industries, a United Arab Emirates generic pharmaceutical company, in collaboration with Cigalah Group, a healthcare distributor, has opened a new \$53-million pharmaceutical manufacturing plant for oral solid dosage and oral liquid formulation drug products in Saudi Arabia's King Abdullah Economic City. [Read More](#)

8. [US Gov't, Sanofi Update Production Shortfall for Yellow-Fever Vaccine](#)

Sanofi Pasteur, the vaccines arm of Sanofi, and the US Centers for Disease Control and Prevention have outlined a plan to ensure a continuous yellow-fever vaccine supply in the US following the anticipated depletion of YF-VAX, Sanofi Pasteur's yellow-fever vaccine, in mid-2017 due to manufacturing issues. [Read More](#)

9. [EMA, EU National Regulatory Heads Begin Discussions in Post-Brexit Plan](#)

European Medicines Agency officials and the heads of the national regulatory authorities of the European Union (EU)/European Economic Area member states held a meeting to begin discussion on how to share the workload for evaluating and monitoring medicines without the UK, following the UK's withdrawal from the EU. [Read More](#)

10. [EMA Advises Pharma Companies on Drug Authorization Shift Post-Brexit](#)

The European Medicines Agency has notified marketing authorization holders (MAHs) to prepare for the legal ramifications of shifting drug authorization of centrally authorized medicines in the wake of the UK's withdrawal from the European Union based on a law that requires MAHs to be established in the EU or the European Economic Area. [Read More](#)

***The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!***

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by mailmanager@dcat.org

